Yes, I think CAR-T therapy is, as you know, that it has made massive waves in the world of oncology, not only in hematology, but I think I’m sure that CAR-T will also make inroads into solid tumors, breast cancer, lung cancer, or in the other solid cancers. So my suggestion, so to say, or my anticipation is that the CAR-T will have to be devolved to the smaller centers also. It can’t actually remain concentrated in the larger teaching hospitals because they will sooner or later get inundated and overwhelmed...
Yes, I think CAR-T therapy is, as you know, that it has made massive waves in the world of oncology, not only in hematology, but I think I’m sure that CAR-T will also make inroads into solid tumors, breast cancer, lung cancer, or in the other solid cancers. So my suggestion, so to say, or my anticipation is that the CAR-T will have to be devolved to the smaller centers also. It can’t actually remain concentrated in the larger teaching hospitals because they will sooner or later get inundated and overwhelmed. So a part of it might actually start or be devolved to the smaller centers. We are fully capable. We have got fully functional intensive care. CAR-T is going to be outpatient treatment in the coming future. Autologous transplant has happened in the smaller centers in District General Hospitals in the UK in the past. So why not CAR-T? And I’m very hopeful that if we get accredited by JACIE and the Department of Health, we’ll be able to start CAR-T in a very successful fashion. And that will take massive pressure off the teaching hospitals, you know, like King’s College Hospital, another teaching hospital around the country where the CAR-T is actually happening at the moment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.